Tag Archive for: NTCD-M3

Destiny Pharma – Audited results for the year ended 31 December 2022

Exclusive North American partnering deal worth up to $570m plus royalties secured for NTCD-M3 Phase 3 development plans finalised for XF-73 nasal following scientific advice from FDA and EMA XF-73 dermal commenced clinically enabling safety study sponsored by US Government’s NIAID New XF research projects initiated in cystic fibrosis and oral mucositis Leadership strengthened with appointment of […]

Destiny Pharma plc – Landmark data published on successful NTCD-M3 gut colonisation after fidaxomicin administration

Brighton, United Kingdom – 4 April 2023 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces that data generated from a C. difficile infection (CDI) model study on the ability of M3 (NTCD-M3), a non-toxigenic C. difficile strain, to successfully colonise the gut following administration […]

Destiny Pharm plc – Agreement with Sebela Pharmaceuticals for NTCD-M3

Exclusive collaboration and co-development agreement for NTCD-M3 with Sebela Pharmaceuticals® worth up to $570m plus royalties Partnership with Sebela will finance the future clinical development and commercialization costs of NTCD-M3 in North America Destiny Pharma retains majority rights for Europe and ROW Key strategic target achieved for NTCD-M3 Brighton, United Kingdom – 24 February 2023 – […]